4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases

A compound according to the general Formula (I)

• wherein
• R101 is selected from the group consisting of:
• hydrogen, linear or branched C1-C6 substituted or unsubstituted alkyl, linear or branched C2-C6 alkenyl, and linear or branched C2-C6 alkynyl;
• R102 is selected from the group consisting of:
• hydrogen, linear or branched substituted or unsubstituted C1-C6 alkyl, linear or branched C2-C6 alkenyl, linear or branched C2-C6 alkynyl, —F, —Cl, —Br, —I, —CN, —NH2 , N(C1-C4alkyl)2, and —NO2;
• R104 is selected from the group consisting of:
• hydrogen, linear or branched substituted or unsubstituted C1-C6 alkyl, linear or branched C2-C6 alkenyl, linear or branched C2-C6 alkynyl, —F, —Cl, —Br, —I, —CN, —NH2 and —NO2;
• R103 is selected from substituted or unsubstituted phenyl or pyridine, wherein each substituent is independently selected from the group consisting of linear or branched C1-C6 substituted or unsubstituted alkyl, linear or branched substituted or unsubstituted C1-C6 alkoxy, linear or branched C2-C6 alkenyl, substituted or unsubstituted C2-4 alkenyloxy, linear or branched C2-C6 alkynyl, substituted or unsubstituted C3-7cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted —O—heterocycloalkyl, substituted or unsubstituted C1-4alkylsulfonyl, substituted or unsubstituted mono- and di-(C1-C4alkyl)sulfonamido, —F, —Cl, —Br, —I, —COOH, —CN, —NH2, —OH, —NO2, —NR20R21, —CO—R20, —CO—O—R20, and —CO—NR20R21, wherein R20 and R21 are independently of each other selected from the group consisting of hydrogen, linear or branched substituted or unsubstituted C1-C6 alkyl, acetyl, and substituted or unsubstituted amino;
• R105 is selected from the group consisting of substituted or unsubstituted phenyl or pyridine, wherein each substituent is independently selected from the group consisting of linear or branched C1-C6 substituted or unsubstituted alkyl, linear or branched substituted or unsubstituted C1-C6 alkoxy, linear or branched C2-C6 alkenyl, linear or branched C2-C6 alkynyl, —F, —Cl, —Br, —I, —CN, —NH2, —NO2, —NR20R21, —CO—R20, and —CO—NR20R21, wherein R20 and R21 are independently of each other selected from the group consisting of hydrogen, linear or branched substituted or unsubstituted C1-C6 alkyl, acetyl, and substituted or unsubstituted amino;
• R106 is selected from the group consisting of hydrogen, linear or branched substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C3-4alkenyl, substituted or unsubstituted C3-8-cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted C3-C8 cycloalkyl, and
• —(CH2)q—A, wherein q is an integer selected from 0 to 5 and A is selected from the group consisting of hydrogen, —F, —Cl, —Br, —I, —CN, —NH2, —NO2, linear or branched substituted or unsubstituted C1-C6 alkyl, linear or branched substituted or unsubstituted C1-C6 alkoxy, linear or branched C2-C6 alkenyl, linear or branched C2-C6 alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, and carboxamido substituted with one or two C1-C6 alkyl;
• or
• R106, when M is —NR140—, can form a heterocyclic structure when taken together with the nitrogen of M and R140;
• L is —CR150R151—SO2—M—,
• wherein R150 and R151 are independently selected from the group consisting of hydrogen, linear C1-C3 alkyl and fluorine, wherein M is a bond or —NR140—;
• R140 is selected from the group consisting of hydrogen, linear or branched substituted or unsubstituted C1-C8 alkyl, and substituted or unsubstituted C3-C8 cycloalkyl;
• or, alternatively, —L—R106, when taken together, is selected from the group consisting of:
• and tautomeric forms,
• N-oxides, individual stereoisomers and mixtures of stereoisomers thereof;
• and the pharmaceutically acceptable salts of such compounds.